More than proud to be working @nkinl.bsky.social under the great leadership of @thijnbrummel.bsky.social. His achievements in the field of fundamental sciences ✍️🔬are truly amazing! Congrats Thijn🥳

#ESMOBreast25: Low baseline tumour infiltrating lymphocytes #TILs and nodal involvement may predict #BreastCancer patients with poor prognosis despite pathological complete response to neoadjuvant chemotherapy. #ESMODailyReporter has more 🔗 buff.ly/YmxaCJ7

I just learned a new pathologist joke: “Tumors dont read J Clin Oncol” from Beppe Viale cited by Carsten Denkert. 🧐📔We as researchers oversimplify cancer biology but tumors dont always follow our classifications @myesmo.bsky.social #esmoambassadors #esmobreast25

Thanks to Nadia Harbeck 🙏for the following extremely important remarks: 1) we shouldnt aim for using even 2 gene expression test, one expensive test is enough; 2) instead use a dynamic biomarker: Ki67 drop after endocrine tx. @myesmo.bsky.social #esmoambassadors #esmobreast25

An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example #ESMOAmbassadors @myesmo.bsky.social

The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social #ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social

Really impressive talk by Davide Massa on prognostic value of TILs together with nodal status in patients with TNBC and pCR. Outcome for TIL low and cN+ is not that good. Would additional treatment help? @myesmo.bsky.social #ESMOBreast25 #ESMOAmbassadors

Do you want to know the most recent ins and outs in breast cancer research and treatment? Follow us 👇for the coolest news from #ESMOBreast25 #BCSM @myesmo.bsky.social

📢 #ESMOFellowship applications are now open! The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch and #ClinicalResearch projects. 📅 Apply by: 29 May 2025 🔗 buff.ly/NN5Y1ol

Very very proud of you my friend. You are a star and fantastic scientist!

Please donate!🚵🏽‍♂️💵💰 Last year we received a huge grant 🤩from KWF to launch the internat OPTImaL trial to avoid chemo for low stage BC with many immune cells! We strongly feel that we should do something in return for KWF so we will bike 🚵🏽‍♂️the Alpe d’Huez 💪🏼 www.opgevenisgeenoptie.nl/fundraisers/...

Very good talk by famous statistician #SGBCC2025

Thanks @drsgraff.bsky.social for your amazing report of -again- an amzing session #SGBCC2025

With co-director @vkaklamani.bsky.social of @sabcs.bsky.social we have been working on #SABCS25 program! Stay tuned! Super exciting with stellar line-up of speakers. With @heidefordlab.bsky.social @itsnotpink.bsky.social and many other fantastic faculty members #bcsm

Good to see your here @renemedema.bsky.social

Looking forward to work as senior editor for the @theaacr.bsky.social journal Clin Cancer Res with this 👇 amazing editor-in-chief. Congrats Tim Yap!

We are hiring! www.nki.nl/careers-stud... @nkinl.bsky.social

Important editorial in the @thelancet.bsky.social Wrong decisions endanger Health care in the US and worldwide, especially for people who need it the most! Lets unit and speak up!📣 www.thelancet.com/journals/lan...

This will kill science in the US. This is how China wins. Why is this not on the news? Why are people not more upset about this? grants.nih.gov/grants/guide...

very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

Impressive paper on biomarkers for immunotherapy in RCC! Good to see biomarkers from pharma-sponsored clinical trials!

Interesting paper on neo-antigen specific T cell therapy! Congrats Cell Therapy team @nkinl.bsky.social

Big fan of the concept of immunogenic cell death/inducing immunogenicity with 'conventional' therapies - so really looking forward to reading/hearing more about TONIC2 following the nice work from the original TONIC trial by @marleenkok.bsky.social & team @nkinl.bsky.social 👇

Smart analyses approach in immunotherapy trials #SABCS24 with stellar 🤩 scientists @christinedesmedt.bsky.social @lambrechtslab.bsky.social C. Sotiriou, R. Ali and E. Romero

Great start #SABCS24 with session on Dietary Suppl, Sex, Exercise ‘Sex, Drugs and Rock n Roll’ 💊🍺❤️🏃🏽‍♂️‍➡️with funny joke by @drdonsdizon.bsky.social that his talk will be a ‘quickie’🤣

Exciting to present 🎤 new data #SABCS24 from TONIC2 study, follow-up from rdcu.be/d22kf. Do immune inductions using low dose dox or cisplatin indeed benefit pts? See us at P1-7-30 and during PS17-9 we show data on TME during acquired resistance to aPD1. With V. Geurts @nkinl.bsky.social @oncoalert

#SABCS24 is a good test who and how many breast cancer research folks decided wisely to move to from X to @bsky.app 🧐. Looking forward to lively comments on the exciting new data we will see in the coming days @oncoalert.bsky.social @oncbrothers.bsky.social @oncodaily.bsky.social

Welcome to #SABCS24 Faculty🚨 @erikahamilton9.bsky.social @hoperugo.bsky.social @drsgraff.bsky.social @maryamlustberg.bsky.social @raalbany.bsky.social @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @stolaney1.bsky.social @fernandoonco.bsky.social @coffeemommy.bsky.social

Recent Nature paper on phase of menstrual cycle at start of breast cancer chemo suggests that this can affect chemo-sensitivity. More research needed on how this can result in cycle-driven-chemo-start. 💊💉Congrats ⁦‪@vanRheenen_Lab‬⁩ ⁦‪@NKI_nl‬⁩ rdcu.be/d2p2l

The PhD program @nkinl.bsky.social is excellent! NKI is the place to be for top-notch cancer research while working in a fantastic open and friendly atmosphere👇

The results of the SONIA trial on the early vs deferred use of CDK4/6i in advanced breast cancer are now published in @Nature No statistically significant benefit for the use of CDK4/6i as a first-line compared with second-line treatment @oncoalert.bsky.social www.nature.com/articles/s41...

Insightful translational study on chemo+IO in eTNBC dissecting chemo response vs IO response! Well done GBG! @cellpressnews.bsky.social #bcsm @oncoalert.bsky.social